UCSF UC San Francisco Previously Published Works

Title

Modular design of synthetic receptors for programmed gene regulation in cell therapies

Permalink

https://escholarship.org/uc/item/3gp4m92w

Journal

Cell, 185(8)

ISSN

0092-8674

Authors

Zhu, Iowis Liu, Raymond Garcia, Julie M <u>et al.</u>

Publication Date

2022-04-01

DOI

10.1016/j.cell.2022.03.023

Peer reviewed



HHS Public Access

Author manuscript *Cell.* Author manuscript; available in PMC 2023 April 14.

Published in final edited form as:

Cell. 2022 April 14; 185(8): 1431–1443.e16. doi:10.1016/j.cell.2022.03.023.

Modular Design of Synthetic Receptors for Programmed Gene Regulation in Cell Therapies

lowis Zhu^{1,2,*}, Raymond Liu^{1,2,*}, Julie M. Garcia^{1,2}, Axel Hyrenius-Wittsten^{1,2,3}, Dan I. Piraner^{1,2}, Josef Alavi^{1,2}, Divya V. Israni⁴, Bin Liu^{2,6,7}, Ahmad S. Khalil^{4,5}, Kole T. Roybal^{1,2,7,8,9,10,11,†}

¹Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, 94143, USA

²Parker Institute for Cancer Immunotherapy, San Francisco, California, 94143, USA

³Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, 221 84, Sweden

⁴Department of Biomedical Engineering and Biological Design Center, Boston University, Boston, MA, 02215, USA

⁵Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA

⁶Department of Anesthesia, University of California, San Francisco, San Francisco, CA 94110, USA

⁷Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, 94158, USA

⁸Chan Zuckerberg Biohub, San Francisco, California, 94158, USA

⁹Gladstone UCSF Institute for Genetic Immunology, San Francisco, CA, 94107, USA

[†]Corresponding author: kole.roybal@ucsf.edu.

^{*}These authors contributed equally to this work.

AUTHOR CONTRIBUTIONS

I.Z. and R.L. conceived and designed the study and performed experiments and vector construction and analyzed data. J.M.G. and A.H-W. performed and analyzed *in vivo* experiments; D.P. and D.V.I. designed vectors and performed experiments related to synthetic zinc fingers; J.A. performed *in vito* experiments. A.S.K. and K.T.R. conceived and designed the study regarding synthetic zinc finger transcription factors. B.L. aided in design of ALPPL2 SNIPR circuits and the development and evaluation of xenograft tumor model experiments. K.T.R. torceived and designed the study and designed the study and designed experiments. K.T.R. I.Z. and R.L. and wrote the manuscript.

DECLARATION OF INTERESTS

I.Z., R.L., and K.T.R. are co-inventors on patents for synthetic receptors (PRV 62/905,258, 62/905,262, 62/905,266, 62/905,268, 62/905,251, 62/905,263). R.L. and K.T.R. are co-inventors on patents for synthetic receptors PRV 62/007,807. R.L., I.Z., D.P., D.V.I., A.S.K. and K.T.R. are co-inventors for synthetic receptors PRV 63/007,795. K.T.R. is a cofounder of Arsenal Biosciences, consultant, SAB member, and stockholder. K.T.R. is an inventor on patents for synthetic Notch receptors (WO2016138034A1, PRV/ 2016/62/333,106) and receives licensing fees and royalties. The patents were licensed by Cell Design Labs and are now part of Gilead. He was a founding scientist/consultant and stockholder in Cell Design Labs, now a Gilead Company. K.T.R. holds stock in Gilead. K.T.R. is on the SAB of Ziopharm Oncology and an Advisor to Venrock. A.S.K. is a scientific advisor for and holds equity in Senti Biosciences and Chroma Medicine and is a co-founder of Fynch Biosciences and K2 Biotechnologies. B.L. is an inventor on patents (WO2017095823A1 and US20180369409A1) held by University of California that cover ALPPL2-targeted anticancer therapy and ALPPL2-targeting antibodies. Unrelated to this work, B.L. is a founder and stockholder of Fortis Therapeutics and Vivace Therapeutics, and a consultant for Merck Sharpe & Dohme.


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

¹¹Lead contact

SUMMARY

Synthetic biology has established powerful tools to precisely control cell function. Engineering these systems to meet clinical requirements has enormous medical implications. Here, we adopted a clinically driven design process to build receptors for the autonomous control of therapeutic cells. We examined the function of key domains involved in regulated intramembrane proteolysis and showed that systematic modular engineering can generate a class of receptors we call <u>SyN</u>thetic Intramembrane Proteolysis <u>R</u>eceptors (SNIPRs) that have tunable sensing and transcriptional response abilities. We demonstrate the therapeutic potential of the receptor platform by engineering human primary T cells for multi-antigen recognition and production of dosed, bioactive payloads relevant to the treatment of disease. Our design framework enables the development of fully humanized and customizable transcriptional receptors for the programming of therapeutic cells suitable for clinical translation.

Graphical Abstract



In brief:

The design framework for fully humanized transcriptional receptors for the programming of therapeutic cells.

Keywords

cell therapy; synNotch; CAR T cells; cancer immunotherapy; synthetic biology

INTRODUCTION

Cellular function is influenced by both external and internal stimuli, with responses to these stimuli encoded in the genome. Having control over the cellular transcriptional response to a defined stimulus allows for the development of living, cell-based therapies with programmed therapeutic functions what is natural. In pursuit of this goal, synthetic receptor platforms have been developed, including the Tango (Barnea et al., 2008; Kroeze et al., 2015) and Modular Extracellular Signaling Architecture (MESA) (Daringer et al., 2014) systems, as well as the synthetic Notch receptor (synNotch) (Morsut et al., 2016). Notch and synNotch are type 1 transmembrane proteins that activate through regulated intramembrane proteolysis (RIP), a sequential process that involves ADAM protease-mediated shedding of the extracellular domain (ECD), γ -secretase-mediated cleavage of the transmembrane domain (TMD), and release of an intracellular transcription factor (TF) that traffics to the nucleus (Morsut et al., 2016; Kopan and Ilagan, 2009; Gordon et al., 2009). SynNotch receptors recognize a user-defined membrane-bound antigen via a high-affinity ligand-binding domain (LBD), such as a single-chain variable fragment (scFv) or nanobody and induce custom gene regulation through release of an engineered TF (Morsut et al., 2016).

The first generation synNotch receptor is a powerful tool for engineering cell circuitry for programmed multicellular morphologies (Toda et al. 2018), localized tumor control (Roybal et al., 2016b, Srivastava et al., 2019), multi-antigen tumor recognition (Roybal et al., 2016a, Williams et al., 2020, Hyrenius-Wittsten et al., 2021), and tumor antigen density discrimination (Hernandez-Lopez et al., 2021). Engineered receptors thus hold potential for furthering our understanding of basic biological processes and expanding our therapeutic options in disease. Translating this work into human therapeutic applications is therefore an important engineering goal.

Despite its role in several cell engineering milestones, the original synNotch receptor has known limitations that affect its further advancement to clinical translation. These issues include 1) the use of non-human components that could elicit immune rejection, 2) the lack of clear design rules for building well-expressed receptors with a tunable activity profile, and 3) the large size of the receptor and transcriptional circuit. We originally observed the inflexibility of the original design during our attempts to engineer the human equivalent of synNotch, which is based on murine Notch1 (Fig. S1A, S1B). Receptors built using the human-derived Notch Negative Regulatory Region (NRRs) resulted in poor activation, high ligand-independent signaling, and/or poor expression (Fig. S1B, S1C). Moreover, both human and mouse-derived synNotch were incompatible with multiple transcription factors (TFs) beyond the yeast- and herpesvirus-derived Gal4-VP64 (Fig. S1B). Motivated by these results, we adopted a systematic approach to define functional receptor modules, allowing us to re-engineer the synNotch receptor from the ground up (Fig. 1A).

Through this approach, we have systematically designed, assembled, and tested a large family of <u>SyN</u>thetic <u>Intramembrane Proteolysis Receptors (SNIPRs)</u>. We present design principles of synthetic receptors that undergo RIP and showcase a subset of designs within the larger family that have advantages for synthetic biology and next-generation T cell therapeutics. These optimized SNIPRs are compact in size, well-expressed, compatible with human and humanized synthetic TFs, readily tunable, and are both highly sensitive and specific to their target ligand. We show that these SNIPRs function robustly in SNIPR-chimeric antigen receptor (CAR) dual antigen-sensing circuits *in vivo*, a therapeutic strategy that enhances tumor specificity and therapeutic efficacy of engineered T cells for solid tumors (Hyrenius-Wittsten et al., 2021, Choe et al., 2021). We also show that we can rationally modify SNIPRs to achieve titratable production of therapeutic payloads such as IL-2, enabling spatially controlled and dosed delivery of therapeutic agents by cells at sites of disease. Though we have focused our efforts on T cells, the toolkit of modular core receptor parts we have characterized can be used for a broad range of applications in synthetic biology, basic biology, and cell therapeutics.

RESULTS

SNIPR development through modular assembly of core receptor domains

To engineer SNIPRs, we took a modular approach for receptor assembly to investigate the role of core domains involved in RIP (Fig. 1A). The ECD of Notch1 and other RIP family proteins contain sites of ADAM protease-mediated shedding (Brou et al., 2000; Mumm et al., 2000), and ECD mutations can impact this regulation (Gordon et al., 2009). The TMD is the site of γ -secretase-mediated cleavage and release of the intracellular domain into the cytosol (De Strooper et al., 1999). While γ -secretase is believed to cleave a diverse peptides (Beel and Sanders, 2008; Haapasalo and Kovacs, 2011), certain TMD mutations are known to negatively impact cleavage efficiency (Huppert et al., 2000). The basic amino acid-rich JMD connects the TMD to the TF, stops translocation of the receptor through the membrane, and interacts with γ -secretase and endocytosis machinery (Le Borgne, 2005).

Through a similar design strategy to that used for synNotch, a prototypical SNIPR, we sought to engineer a second example of a functional SNIPR. We selected human Robo1, a RIP receptor family member known for mediating ligand-directed neuronal pathfinding (Coleman et al., 2010). Like Notch, Robo1 is a type-I transmembrane protein that undergoes ECD shedding upon ligand engagement, followed by γ -secretase-mediated TMD cleavage to free the cytoplasmic tail (Seki et al., 2010). The proteolytic core of Robo1 features an ADAM10 protease-sensitive site that is protected by a type III Fibronectin (Fn-III) domain, as well as the receptor TMD and JMD (Coleman et al., 2010). As with synNotch, we built a synthetic Robo1 receptor (synRobo) against CD19 that contained the Robo1 proteolytic core and the Gal4-VP64 TF, combining it with the cognate Gal4 DNA response element (RE) controlling a BFP reporter (Fig. S1A). Although synRobo expressed at a comparable level to synNotch (Fig. S1D), we observed poor reporter activation when T cells expressing the anti-CD19 synRobo were exposed to K562^{CD19+} sender cells (Fig. 1B). To determine the cause of this stark difference in activity, we substituted two key domains of synRobo, the TMD and JMD, with the equivalent domains from human Notch1. We

found that the resulting Robo1/Notch1 chimeric receptor (RoboNotch) was constitutively active, suggesting that the ECD of synRobo was easily shed, but the Robo1 TMD and JMD were not easily processed (Fig. 1B). We also found that deletion of the putative ADAM10 protease site in the Robo1 ECD of RoboNotch significantly reduced constitutive signaling and restored ligand-dependent activation. Thus, a canonical protease cleavage site in the ECD is not necessary for receptor function, but the receptor activity remains dependent on ADAM protease activity (Fig. 1B, S1D).

The assembly of a second functional SNIPR through engineering of domains from Robo1 and Notch1 prompted us to develop a systematic process to explore the principles of receptor design. We thus built a set of SNIPRs to identify critical features of the ECD, TMD, and JMD that are necessary for optimal receptor function. We began with the ECD, constructing a set of SNIPRs with a series of flexible glycine-glycine-serine repeats ECDs of variable lengths, an anti-CD19 scFv, and the human Notch1 TMD and JMD. These designs were expressed in human T cells and demonstrated ligand-dependent activation across all tested ECD lengths, as well as a dependence on ADAM protease activity (Fig. 1C, S1E). Given that a simple ECD without known protease sites was sufficient for regulated receptor activity, we considered that a broad range of ECDs could be used to assemble functional SNIPRs when paired with a RIP-permissive TMD and JMD. We further hypothesized that additional TMDs and JMDs may be compatible with heterologous ECDs, enabling the modular construction of a family of SNIPRs with diverse activation properties for more customized cellular programming.

ECD engineering controls SNIPR activation parameters

Given our positive results with a Robo-derived ECD and simple linkers, we expanded our survey of ECDs to include synthetic peptides with embedded protease sites, Notchderived domains, and well-characterized hinge domains sourced from chimeric antigen receptors (CARs). We found that SNIPRs built with synthetic linkers containing exposed ADAM protease sites were constitutively active, while a SNIPR built with a FLAG-tag linker containing an enterokinase cleavage site retained ligand-dependent activity (Fig. 2A). Interestingly, an ECD that incorporated fibroblast activation protein (FAP) cleavage sites demonstrated signaling when co-cultured with K562 cells, an effect that was abrogated with the addition of an LBD, suggesting that ECD shedding is dependent on protease availability and cleavage site accessibility (Fig. 2A, S2A).

Given the diversity of functional ECDs in SNIPRs, we decided to assess whether a regulatory domain such as the Notch NRR was necessary for receptor function. This SNIPR design with a full deletion of the Notch1 NRR (NRR) exhibited strong ligand-induced signaling but was also triggered by T cell activation alone (Fig. 2A). T cell activation-based receptor activity was observed with several methods of T cell activation, including with the use of a Bi-specific T cell Engager (BiTEs) or a co-expressed second generation CAR (Fig. 2B, S2B). This behavior was not observed in similar truncation variants of the other three human Notch proteins (Fig. S2C). In addition, we observed that T cell activation drove the enhanced activation of SNIPRs, such as synNotch, that appeared insensitive to T cell activation alone (Fig. 2B). These data demonstrate that a spectrum of ECDs is compatible

with SNIPR construction and that the choice of ECD can impact the fidelity and sensitivity of the receptor (Fig. 2B, S2C).

Clinically oriented ECD engineering

CARs often include a hinge region derived from immunoglobulin-like domains, such as CD8a or CD28, or from trimeric receptors (e.g. OX-40) in the ECD that affects critical aspects of CAR activity (Guedan et al., 2019). We found that, when used in our SNIPR designs, CD8a and CD28-based hinge ECDs exhibited high expression and receptor activation, with the CD8a hinge exhibiting reduced ligand-independent signaling and thus a better signal-to-noise ratio (Fig. 2A, S2D). However, the full-length CD8a hinge displayed ligand-independent signaling with T cell activation, especially in CD8+ T cells (Fig. S2D, S2E). Given these results, we devised a strategy to improve the functionality of the CD8a hinge ECD through a series of N-terminal and C-terminal region of the CD8a hinge displayed enhanced expression and minimal ligand-independent activity with T cell activation (Fig. 2C, S2F). This optimized CD8a hinge SNIPR was nominated for additional development due to its efficient, high-fidelity activation and compact size, with the full optimized anti-CD19 CD8a hinge SNIPR with Gal4-VP64 being only 1.65kB in length whereas the original synNotch is 2.45kB, a 33% reduction in size.

TMD and JMD engineering can tune receptor activity

The Notch1 TMD and JMD are functional with a broad set of ECDs (Fig. 2A). We next investigated the characteristics of the domains that make them functional, and whether additional TMD or JMD sequences were compatible with SNIPR assembly. To do this, we compiled a list of proteins known to undergo RIP and extracted their TMD and JMD sequences (Haapasalo and Kovacs, 2011) (Fig. 3A, Table S1). We defined the JMD as a stretch of basic amino acids (R/K/H) beginning immediately C-terminal to the TMD and ending before three consecutive non-basic amino acids. Due to the diversity observed in both TMDs and JMDs, we decoupled the TMD-JMD pair into two separate modules for screening and compiled 88 TMDs and 76 JMDs (Table S2, S3). We then inserted them individually into a human synNotch scaffold, replacing the respective Notch1 components, and screened them for receptor activity using a Jurkat reporter cell line in an arrayed format (Fig. 3A, Table S4, S5). We analyzed the TMDs displaying >50% activity to that of the Notch1 TMD or JMD for sequence similarities and identified additional TMDs and JMDs of interest for further testing (Fig. 3B, 3C).

The top performing TMDs were mainly from the Notch and Calsyntenin (CLSTN) protein families, with the activity of most TMDs below 50% of that of Notch1 (Fig. 3B). Alignment of the Notch and CLSTN TMD sequences reveals a common c-terminal glycine-valine motif associated with γ -secretase cleavage. Previous studies have shown that these sites are essential for efficient intramembrane processing by presenilin (Vooijs et al., 2004; Okochi, 2002). To determine the importance of this motif in SNIPR signaling, we performed an alanine scan within the Notch1 TMD in primary human T cells, using the optimized CD8 α hinge Notch ECD and Notch1 JMD (Fig. 3B). Although receptor expression was not reduced (Fig. S3A), we found that substitution of the glycine (G318A) and invariant valine

(V319A) reduced receptor activity by 47% and 75%, respectively. Background signaling activity from these receptor variants was also lower, consistent with decreased processing (Fig. 3B, S3B) (Vooijs et al., 2004; Okochi, 2002). In addition, two otherwise non-functional TMDs, from Robo1 and Advanced glycosylation end product-specific receptor (AGER), could be made functional through the addition of a glycine-valine motif and removal of bulky residues near the TMD c-terminus (Fig. S3C).

In contrast to the TMD screen, our results from the JMD screen showed that JMDs sourced from a diverse set of proteins were effective in a SNIPR context (Fig. 3C, Fig. S3D). We found that the top JMD sequences favored basic residues immediately adjacent to the membrane, with basic or polar residues composing the first 4 to 6 amino acids, and at least two R/Ks within the first 3 amino acids. Hydrophobic or acidic residues within this stretch were found to inhibit receptor activation. Replacement of either the Notch1 TMD or JMD did not affect SNIPR sensitivity to T cell activation alone, suggesting that T cell activation affects SNIPR ECD cleavage.

Building non-Notch SNIPRs from functional parts

Thus far, all functional SNIPRs we have studied include sequences derived from the Notch family. To demonstrate the versatility of our modular assembly approach, we engineered a functional ligand-activated receptor without Notch domains, combining the optimized CD8a hinge ECD with the CLSTN2 TMD and functional JMD modules discovered in our screens. Although all receptors expressed (Fig. S3E), the otherwise-active CLSTN2 TMD did not function with its cognate JMD (RVRIAHQH), an expected result given the poor performance of the CLSTN2 JMD in our screen (Fig. 3C). However, receptor functionality was restored by replacing the JMD with that of AGER (RRQRR) or Protein tyrosine phosphatase receptor type F (PTPRF) (KRKRTH), two potent JMDs identified in our screen (Fig. 3D, S3E). Our ability to build functional SNIPRs from a set of functional parts demonstrates that we can tune receptor sensing and activity with modular engineering (Fig. S3E).

Precision control and customization of T cell therapeutics with SNIPRs

Based on the design principles of SNIPRs we uncovered, we next assembled receptors from a menu of ECDs, TMDs, and JMDs with a range of activation characteristics. Our design criteria included robust expression, a range of ligand-dependent activation levels, and low ligand-independent activation (Fig. 4A, S4A). For the ECD, we selected the optimized CD8a hinge, due to its strong expression, compact size, and selective response to ligand. We then screened through a selection of high-performing TMDs and JMDs, using a constant Notch1 JMD or TMD, respectively. From this process, we decided to keep the Notch1 TMD due to its robust activation and best-in-class levels of ligand-independent signaling, along with the ready availability of mutants for tunability (Fig. 4A). We screened this ECD-TMD combination against a panel of JMDs, choosing a set of SNIPRs with a range of activation levels. Although SNIPR expression levels varied between TMDs and JMDs, these differences did not always correlate with SNIPR activation, supporting a role for the JMD in affecting activity beyond impacting expression. The set of SNIPRs remained sensitive to

ADAM protease and γ -secretase inhibition, suggesting a continued role for these proteases in SNIPR activation (Fig. S4B).

Having extensively investigated the range of domains that can be used to build functional SNIPRs, we determined how to utilize these receptors to control the therapeutic function of T cells. Many cancers adapt to CAR T cell therapy through antigen escape, downregulating their levels of surface CAR antigen (Majzner and Mackall, 2018). Having observed that our SNIPRs exhibited improved activation to CD19, we decided to test their ability to sense a range of surface antigen levels. To do this, we activated T cells engineered with alkaline phosphatase placental-like 2 (ALPPL2) targeted SNIPRs with a K562 cell line that expresses the tumor-specific antigen ALPPL2 in response to Doxycycline (Hyrenius-Wittsten, 2021) (Fig. 4B, S4C, S4D). We were able to achieve expression levels from 8×10^3 to 9.9×10^5 molecules of ALPPL2 per K562 (Fig. 4B). The optimized CD8a Hinge Notch SNIPR is more sensitive to lower ligand levels than synNotch without an increase in basal activity and that use of the Notch2 JMD further boosts sensitivity (Fig. 4C, 4D). These data suggest that SNIPRs could be useful in a wider array of immunotherapeutic applications where antigen density is heterogenous across the tumor mass.

Immune cell function is regulated by cytokines in a dose-dependent fashion, and side effects occur when a high dose of cytokines is given systemically as an immunotherapeutic (Pachella et al., 2015). Given that SNIPR activity is readily tuned through the TMD and JMD, we wanted to show how SNIPRs can be used to drive defined levels of the engineered T cell growth factor, super IL-2 (Levin et al., 2012). To do this, we built single viral vector constructs containing SNIPRs with a range of activity levels and an inducible super IL-2 cassette (Fig. S4E). We observed that CD4+ T cells expressing a SNIPR with the enhancing Notch2 JMD secreted higher amounts of super IL-2 in response to ligand expressed on K562 sender cells that had been irradiated to prevent culture overgrowth, while those with the additional dampening TMD mutation G318A secreted lower amounts of super IL-2 (Fig. 4E). The different amounts of induced super IL-2 produced by each SNIPR circuit correlated with T cell proliferation rates, exhibiting our ability to tune therapeutic T cell activity, and did not correlate purely with SNIPR expression levels (Fig. 4F, S4F). While we use the example of super IL-2 to demonstrate the capabilities of the SNIPR platform, this principle of receptor tuning can be applied toward a broad range of therapeutic programs (Roybal et al., 2016a). Indeed, we have found high-performing SNIPRs to be compatible with a wide array of LBDs (Fig. S4G).

Development of humanized SNIPRs with potential for clinical translation

We have explored the core regulatory domains (ECD, TMD, and JMD) that control the ligand-dependent cleavage of SNIPRs and have identified optimized cores. However, the synthetic Gal4-VP64 TF is a design liability for clinical translation as it is derived from yeast (Gal4) and herpesvirus proteins (VP64). To engineer a humanized receptor, we constructed TFs comprised of DNA-binding domains (DBD) fused to the transactivation domain of human NF- κ B p65. We examined both DBDs sourced from human proteins, as well as engineered orthogonal synthetic zinc fingers (synTFs), for their ability to function in the SNIPR context (Fig 5A). Human protein-derived DBDs are advantageous

for minimizing immunogenicity, whereas synTFs minimize off-target effects as verified by RNA-seq (Israni et al., 2021). Human protein-derived DBDs were chosen based on size and lack of expression in T cells (Uhlen et al., 2015), and included the eye developmentassociated paired box protein Pax-6 (Pax6) (Xu et al., 1999) and the liver-specific protein hepatocyte-nuclear factor 1-alpha (HNF1A) (Roscilli et al., 2002). SynTF candidates were selected for their orthogonality and potent transcriptional activity (Israni et al., 2021). RE cassettes for these TFs were constructed by tandem assembly of cognate binding motifs upstream to a minimal promoter. These RE cassettes proved to be orthogonal in T cells, as they were not activated in the absence of target cells (Fig. 5B). Humanized SNIPRs activated to target cells, and activation varied across TFs, suggesting that circuit function is subject to the efficiency of each TF in driving transcriptional activation (Fig. 5B). To examine whether TF compatibility extends to the original synNotch receptor, we tested the two TFs with the highest activation, HNF1A and ZF10, with the mouse synNotch and humanized receptor variant, and found that neither expressed nor activated as efficiently as the equivalent CD8a Hinge Notch SNIPRs (Fig. 5C, S5A). Compared to the Gal4-based receptor, Pax6 and HNF1A-based SNIPRs are comprised of peptide sequences with predicted immunogenicity on par with current clinical CAR designs, greatly reducing the risk of rejection in therapeutic applications (Fig. 5D). We found that peptides predicted to be most immunogenic are at junctions and thus could be eliminated by adjusting linker sequences without affecting receptor function. We examined whether a humanized anti-CD19 SNIPR→CAR circuit can eliminate target cells, an important benchmark for clinical utility. We found that HNF1Abased SNIPRs induced expression of an anti-BCMA CAR at a slower rate than Gal4-based SNIPRs, but at sufficient levels to clear in vitro tumor targets (Fig. S5B, S5C, S5D). We also found that functional SNIPR circuits could be integrated at low vector copy numbers (VCN), meeting requirements for clinical manufacturing (Fig. S5E). Finally, to further assess clinical viability, we performed RNA-sequencing to examine the transcriptomes of SNIPR-T cells utilizing HNF1A, our strongest human TF. We found that SNIPR circuit activation resulted in strong expression of circuit components, with minimal off-target changes in gene expression (Fig. 5E, S5F). Together, these data demonstrate that optimized SNIPR designs compatible with a broad range of TFs can overcome major obstacles to clinical translation.

In vivo testing of SNIPR-CAR circuits

Current challenges in CAR immunotherapy include the difficulty in defining a tumor with a single antigen. Systemic and unintended toxicity through on-target, off-tumor CAR activity has limited the clinical development of CARs and potent cytokine therapies (Ellis et al., 2021; Morgan et al., 2010). A multi-antigen recognition platform where a SNIPR binds a primary tumor antigen and drives expression of a CAR to a secondary antigen helps to mitigate risk of toxicity through more precise tumor recognition, and our humanized SNIPRs reduce the chance for immune rejection (Roybal et al., 2016b).

Humanized SNIPR \rightarrow CAR circuits performed with high-fidelity during *in vitro* testing, but the question remained of their performance *in vivo*, where they would be exposed to a more diverse set of proteases and other environmental factors. To assess the performance and specificity of the optimized CD8 α hinge SNIPRs *in vivo*, we examined the ability of

SNIPR circuit T cells to control tumor growth in dual-antigen xenograft models. To test our benchmark anti-CD19 SNIPR→anti-BCMA CAR circuit *in vivo*, CD19+/BCMA+ K562 tumors were implanted in the left flank, and BCMA+ K562 tumors were implanted in the right flank of NOD.Cg-*Prkdc^{scid}II2rg^{tm1Wjl}*/SzJ (NSG) mice. Four days after implantation, these mice were treated with untransduced T cells, anti-BCMA CAR T cells, or anti-CD19 SNIPR circuit T cells containing either a Gal4-VP64- or HNF1A-p65-driven anti-BCMA CAR (Fig. S6A, S6B). The anti-BCMA CAR and anti-CD19 SNIPR→anti-BCMA CAR circuit T cells selectively controlled dual-positive tumor growth. These data support the potency and specificity of SNIPR→CAR circuits in an *in vivo* setting and represent a successful demonstration of a humanized circuit *in vivo*. As a further assessment of specificity of the SNIPR→CAR circuit T cells, we harvested the tumors and spleen and observed BCMA CAR expression only in the dual antigen target tumor (Fig. S6F–H).

We next examined whether our humanized SNIPR circuits can specifically recognize clinically relevant antigen pairs for solid tumors. We recently reported ALPPL2 as a tumor specific antigen that can be targeted in combination with the tumor-associated antigens mesothelin or HER2 in mesothelioma or ovarian cancer, respectively (Hyrenius-Wittsten et al., 2021). We examined the ability of humanized anti-ALPPL2 SNIPR→anti-HER2 CAR circuits to eliminate dual-antigen ovarian cancer SK-OV-3 cells, both in vitro and in vivo. Using live cell imaging assays, we observed that SNIPR-CAR T cells cleared ALPPL2+/HER2+ SK-OV-3 but not HER2+ only cells (Fig 6A). Kinetic analysis showed that SNIPR circuit-mediated cytotoxicity was slower than CAR-T cell killing, due to the time needed for CAR induction as previously observed (Fig 6B) (Hyrenius-Wittsten et al., 2021). To examine in vivo efficacy, ALPPL2+/HER2+ and ALPPL2-/HER2+ SK-OV-3 cells were implanted in the left and right flanks, respectively, of NSG mice. Eight days after implantation, these mice were treated with untransduced T cells, anti-HER2 CAR T cells, or anti-ALPPL2 SNIPR→anti-HER2 CAR circuit T cells (Fig 6C). Anti-HER2 CAR-T cells and anti-ALPPL2 SNIPR→anti-HER2 CAR circuit T cells controlled tumor growth in the dual-positive tumor, but only the HER2 CAR controlled tumor growth in the single-positive tumor. Analysis of SNIPR T cell activation and CAR expression in the spleen, dual-positive, and single-positive tumors in a repeat experiment found specific SNIPR-T cell infiltration and CAR expression in the dual-positive tumor (Fig. 6D-G). Similarly, we observed that SNIPR circuits could specifically clear ALPPL2+/Mesothelin+ M28 epithelioid mesothelioma (Fig S6I, S6J). Together, these data demonstrate the clinical potential of humanized SNIPR-CAR circuits for more precise recognition of solid tumor targets.

DISCUSSION

From our investigations into the ECDs, TMDs, and JMDs of RIP receptors, we have constructed a large set of receptors that function like Notch and have begun to define the guidelines for the synthetic assembly of these receptors we call SNIPRs (Fig. 7, Tables S2, S3). Overactive, inactive, and suboptimal core domains that control RIP all significantly reduce SNIPR performance, even when assembled with functional domains at other positions, suggesting that all three domains must be optimized for maximum ligand-dependent cleavage. We find that ECD specificity can be optimized by avoiding exposed

Cell. Author manuscript; available in PMC 2023 April 14.

protease sites and minimizing length, although SNIPR activity in response to alternative stimuli, such as T cell activation, may require direct observation to discover. We also find that additional TMDs and JMDs can be used to construct SNIPRs, and that TMDs and JMDs can be tuned through point mutations to meet individual clinical requirements, such as improving specificity or regulating levels of a delivered therapeutic. In addition, we find that SNIPRs containing suboptimal modules, such as the human synNotch ECD, can be improved through either direct ECD engineering, such as deletion of the NRR (Fig. 2A, 2B), or increasing activity in another module, such as the JMD. All three core SNIPR components, along with the LBD and TF, can impact receptor expression. Our systematic exploration of SNIPR parts identified receptors that are well-expressed and activate with high fidelity, two key features for cell therapy.

We have found that many SNIPR ECDs that lack regulatory domains such as the NRR remain functional. This result adds to previous screens of ECDs in a Notch context, which found that proteolytic switches with homology to Notch could substitute for the Notch NRR, albeit with a reduced signal-to-noise ratio (Hayward et al., 2019). In contrast, we find that ECDs with no homology with Notch outperform it in the context of a synthetic receptor. One commonality between functional ECDs is a relative lack of known protease cleavage sites. While a simple glycine-serine linker is a sufficient ECD, we find the addition of ADAM or MMP9 cleavage sites to this inherently unstructured linker leads to uncontrolled SNIPR activation. In addition, removal of known ADAM10 cleavage sites in the Robo1 and Notch1 ECDs improved the signal-to-noise ratios for SNIPRs utilizing these components. This discovery suggests that there is a large realm of permissive ECDs with a common mechanism of activation. Although most SNIPRs exclude known sites for ADAM protease cleavage, we find that all tested SNIPRs continue to rely on ADAM protease and γ -secretase activity. Our finding of enhanced SNIPR signaling during T cell activation may be explained by higher ADAM10 and ADAM17 activity (Li et al., 2007, Lambrecht et al., 2018), but the mechanism for either ligand-dependent or -independent activation for the SNIPRs requires further study. The mechanism of Notch activation through RIP is well-investigated, but the roles of other cellular processes, such as ubiquitination (Moretti et al., 2013), receptor endocytosis (Kandachar and Roegiers, 2012), and receptor trafficking (Yamamoto et al., 2009) remain unclarified and could regulate SNIPR activity.

We were surprised to observe a lack of diversity in high-performing TMDs, having selected candidate TMDs from reported γ -secretase substrates (Haapasalo and Kovacs, 2011). This finding may be specific for SNIPRs expressed in human T cells, and SNIPRs containing non-functional TMDs from our screen may be more active when expressed in other tissue or cell types.

In conclusion, our systematic engineering of SNIPRs has allowed us to build customizable receptor cores that provide not only the spatial discrimination afforded by previous synthetic receptors, such as synNotch, but also sensitivity at a range of antigen levels and greater compatibility with humanized components, thereby lowering the risk for immunogenicity. This added functionality is of clear benefit to current immunotherapies, such as CAR T cells, and should help provide a titrated therapeutic response while mitigating known issues of these technologies, such as premature T cell exhaustion and on-target/off-tumor systemic

Cell. Author manuscript; available in PMC 2023 April 14.

toxicity. For example, local titrated delivery of a potent cytokine, such as IL-12 (Lasek et al., 2014), to a tumor site using therapeutic cells may significantly improve efficacy and clinical outcomes as compared to the severe toxicity observed during systemic IV administration. These receptors should provide biomedical research with a comprehensive toolkit for directing a range of cell-based therapies to their intended targets combined with programmed localized therapeutic activity.

Limitations of the Study

Limitations of the study include our focus on applying SNIPR technology in human primary T cells. Guidelines that define optimal SNIPR performance, such as TMD and JMD selection, may vary between tissue types and organisms, and a screen of SNIPR performance between a wide array of cell types would be helpful in determining the universality of our SNIPR engineering rules. In addition, while we expect that enhanced SNIPR activity in the context of T cell activation would be beneficial in the context of an induced CAR, where activation of the induced CAR boosts the initial SNIPR signal, any TCR/CAR-mediated boost in SNIPR signaling may be unwanted in situations where only small amounts of an otherwise toxic therapeutic payload are desired. Additional engineering strategies such as TRAC KO (Eyquem et al., 2017) should be considered in these situations where SNIPR-TCR interactions are of concern. Finally, care should be taken to reduce unintended CAR activation at co-localized normal tissues (Srivastava et al., 2019) through the selection of target antigens for SNIPR-CAR circuits and the choice of SNIPR core.

STAR METHODS

RESOURCE AVAILABILITY

Lead contact—Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Kole Roybal (kole.roybal@ucsf.edu).

Material availability—Plasmids generated in this study will be deposited to Addgene.

Data and code availability—All raw data reported in this paper will be shared by the Lead Contact upon request. This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animals—NOD.Cg-*Prkdc^{scid}II2rg^{tm1Wj1}*/SzJ (NSG) mice were used for all *in vivo* experiments. All mice were between 8 and 12 weeks of age at start of experimentation and were not involved in previous procedures. Females were used for all experiments using K562 and SK-OV-3 as target cells, and males were used for all experiments using M28 as target cells. All mice were group housed with a maximum of 5 mice per cage. For experimentation, littermates of the same sex were randomly assigned to experimental groups. All mice were supplemented with amoxicillin/clavulanate (Zoetis) during experimentation for infection prophylaxis. All experimentation was performed in accordance with the IACUC guidelines present at UCSF.

Cell lines—Lenti-X 293T cells originate from female fetal tissue. U87 cells originate from a male patient with malignant glioma, likely glioblastoma. MDA-MB-468 cells originate from a female with breast adenocarcinoma. SKBR3 cells originate from a female with breast adenocarcinoma. Lenti-X 293T, U87, MDA-MB-468, and SKBR3 cells were all cultured in DMEM supplemented with 10% FBS and 50 U/mL penicillin-streptomycin. K562 cells originate from a female with chronic myelogenous leukemia. They were cultured in IMEM supplemented with 10% FBS and 50 U/mL penicillin-streptomycin. Jurkat T cells originate from a male T cell leukemia patient, and M28 cells originate from a human mesothelioma culture. Both were cultured in RPMI-1640 supplemented with 10% FBS, 50 U/mL penicillin-streptomycin, and 1X Glutamax (ThermoFisher). SK-OV-3 cells originate from a female with 10% FBS and 50 U/mL cell lines are cultured in a 37°C incubator with 5% CO₂.

Primary Human T cell Isolation and Culture—Primary CD4+ and CD8+ T cells were isolated from anonymous donor blood after apheresis by negative selection (STEMCELL Technologies #15062 & 15063). Blood was obtained from Blood Centers of the Pacific (San Francisco, CA) as approved by the University Institutional Review Board. T cells were cryopreserved in RPMI-1640 (Thermo Fisher #11875093) with 20% human AB serum (Valley Biomedical Inc., #HP1022) and 10% DMSO. After thawing, T cells were cultured in human T cell medium consisting of X-VIVO 15 (Lonza #04-418Q), 5% Human AB serum and 10 mM neutralized N-acetyl L-Cysteine (Sigma-Aldrich #A9165) supplemented with 30 units/mL IL-2 (NCI BRB Preclinical Repository) for most experiments. For experiments involving the induction of super IL-2, primary T cells were maintained in human T cell media supplemented with IL-2 until experimentation, whereupon media was replaced with media without supplemental IL-2.

Bacteria—Stellar chemically competent E. coli, a HST08 strain, (Takara) were used for molecular cloning. They were cultured in LB broth supplemented with a selection antibiotic at 37°C in a shaker set to 250 rpm or on LB-agar plates supplemented with a selection antibiotic at 37°C in a plate incubator.

METHOD DETAILS

Receptor and Response Element Construct Design—Receptors were built by fusing the CD19 scFV (Porter et al., 2011), ALPPL2 M25^{FYIA} scFV (Hyrenius-Wittsten et al., 2021), HER2 4D5-8 scFv (Carter et al., 1992), EGFRviii 139 scFv (Morgan et al., 2012), or LaG17 nanobody (Fridy et al., 2014) to an extracellular domain comprised of: the human Notch1 (P46531) minimal regulatory region (Ile1427 to His1735), a truncated human Notch1 Notch Regulatory Region (Ile1427 to Glu1447, Thr1725 to His1735), a CD8a (P01732) hinge region (Thr138 to Asp182), a CD28 (P10747) hinge region (Ile114 to Pro152), an IgG4 hinge region, an OX40 hinge region, (the type III fibronectin domain from Robo1 (Q9Y6N7, Lys769 to Pro897), truncated CD8a hinges and fibronectin domains (as described), or Gly-Gly-Ser linkers of variable length (as described). All extracellular domains (as described), and a transcriptional element composed of Gal4 DBD VP64, Pax6(M1

to Ala139)-p65(Pro428 to Ser551), HNF1A(Met1 to Met283 with Thr-Cys-Arg linker)p65(Asp361 to Ser551), or ZF-p65 (14). All receptors contain an N-terminal CD8a. signal peptide (MALPVTALLLPLALLLHAARP) for membrane targeting and a myc-tag (EQKLISEEDL) for easy determination of surface expression with α -myc AF647 (Cell-Signaling #2233). The receptors were cloned into a modified pHR'SIN:CSW vector containing a PGK promoter for all primary T cell experiments. The pHR'SIN:CSW vector was also modified to make the response element plasmids. Five copies of the Gal4 DNA binding domain target sequence (GGAGCACTGTCCTCCGAACG), or four copies of the Pax6 consensus DBD recognition motif (ATTTTCACGCATGAGTGCACAG) and HNF1A DBD recognition motif (GTTAATNATTAAC) were cloned 5' to a minimal synthetic pybTATA promoter. Also included in the response element plasmids is a PGK promoter that either constitutively drives expression of a fluorophore (mCitrine or mCherry) to easily identify transduced T cells or a SNIPR for single vector experimentation. Inducible CAR vectors contained CARs tagged N-terminally with FLAG-tag, and in some cases C-terminally with a t2a GFP system. All induced elements were cloned via a BamHI site in the multiple cloning site 3' to the Gal4 response elements. All constructs were cloned via In-Fusion cloning (Takara # 638951).

Lentiviral Transduction of Human T cells—Pantropic VSV-G pseudotyped lentivirus was produced via transfection of Lenti-X 293T cells (Clontech #11131D) with a pHR'SIN:CSW transgene expression vector and the viral packaging plasmids pCMVdR8.91 and pMD2.G using Mirus Trans-IT Lenti (Mirus #MIR6606). Primary T cells were thawed the same day, and after 24 hours in culture, were stimulated with Human T-Activator CD3/CD28 Dynabeads (Life Technologies #11131D) at a 1:3 cell:bead ratio. At 48 hours, viral supernatant was harvested, and the primary T cells were exposed to the virus for 24 hours. At day 5 post T cell stimulation, the Dynabeads were removed, and the T cells were sorted for assays with a Beckton Dickinson (BD) FACs ARIA II. Sorted T cells were expanded until day 10 for *in vivo* assays and until day 14 for *in vitro* assays.

Generation of Receptor Jurkat cells for Screening—E6-1 Jurkat T cells (ATCC# TIB-152) were lentivirally transduced with a reporter plasmid encoding a Gal4 driven tagBFP response element and a constitutively expressed mCitrine cassette. Reporter positive cells were sorted for mCitrine positivity and expanded. Individual cultures of reporter positive Jurkat T cells were lentivirally transduced in a 96 well plate with myc-tagged a-CD19 human SynNotch1 receptors with modified transmembrane or juxtamembrane domains. After viral transduction, the receptor transduction efficiency for each Jurkat cell population was measured with a BD FACSymphony Fortessa X-50 following staining with anti-myc AF647 (Cell-Signaling #2233).

Cancer Cell Lines for Screening—The cancer cell lines used were K562 myelogenous leukemia cells (ATCC #CCL-243). K562s were lentivirally transduced to stably express either human CD19 at equivalent levels as Daudi tumors (ATCC #CCL-213), BCMA, or both BCMA and CD19. CD19 levels were determined by staining the cells with α -CD19 APC (Biolegend #302212). BCMA levels were determined by staining the cells with

 α -BCMA APC (Biolegend #357505). All cell lines were sorted for expression of the transgenes.

MCAM BiTE Production—MCAM BiTE was produced from transfecting LentiX-293T cells with a pHR'SIN:CSW transgene expression vector. 293T media was replaced with T cell media 24 hours after transfection. MCAM BiTE was harvested 48 hours post-media replacement by collecting supernatant and removing 293T cells via centrifugation.

Doxycycline inducible ALPPL2—A clonal line of K562 cells expressing a doxycyclineinducible FLAG-tagged ALPPL2 cassette was treated with doxycycline (Abcam) at doses ranging between 0.1–100 ng/mL for 24 hours prior to co-incubation with T cells. Surface expression levels were assessed by flow cytometry using an PE-conjugated anti-FLAG antibody (Biolegend) prior to assay. Surface ligand levels were quantified using a Quantibrite PE Phycoerythrin Fluorescence Quantitation Kit (BD Biosciences).

In vitro SNIPR Activation Assays—For *in vitro* SNIPR activation assays, 1×10^5 T cells or Jurkat T cells were co-cultured with the indicated target cells at a 1:1 ratio. Co-cultures were performed in 96 well round bottom plates for K562 target cells (VWR) and 96 well flat bottom plates (VWR) for all other target cell lines. Adherent target cells were plated 1 day prior to co-culture with T cells. To exogenously activate T cells, MCAM BiTEs were added to co-cultures when indicated. When activating a co-expressed ALPPL2 CAR, ALPPL2+ K562 cells were added to the co-culture in a 1:1 ratio with T cells. The cultures were analyzed at the time points indicated for reporter activation using a BD FACSymphony Fortessa X-50. All flow cytometry analysis was performed in FlowJo software (BD). TMD sequence alignment was performed using ClustalX and visualized using Jalview.

Incucyte killing assay—For *in vitro* engineered T cell killing assays, ALPPL2+/HER2+ or ALPPL2-/HER2+ SK-OV-3 tumor cells expressing nuclear mKate2 were seeded in 96-well flat-bottom plates. After 24 hours, engineered T cells were added at an expected effector:target ratio of 1:1. Plates were imaged every 2 hours using the IncuCyte S3 Live-Cell Analysis System (Essen Bioscience) for a duration of 14 days. Three images per well at ×10 magnification were collected. Experiments were performed in RPMI 1640 with 10% FBS, penicillin (100 U/ml) and streptomycin (100 μ g/ml), and 1× GlutaMAX supplemented with IL-2 (30 U/ml). Media was replaced every 5 days.

Super IL-2 Induction Assays—For proliferation assays, primary CD4+ were stained with Cell Trace Violet (Thermo Fisher #C34557) and stimulated with irradiated K562 or CD19+ K562 target cells in human T cell media without IL-2 supplementation. T cell division was assayed using flow cytometry at the indicated time points using a BD FACSymphony Fortessa X-50. For induced super IL-2 quantification, CD4+ T cells were stimulated with irradiated K562 or CD19+ K562 target cells in human T cell media without IL-2 supplementation and supernatant was harvested at the indicated timepoints. Super IL-2 levels in the supernatant were measured using an IL-2 Human Instant ELISA kit (Thermo Fisher #BMS221INST).

Vector Copy Number Measurements—Vector copy number was measured using a previously described droplet digital PCR method (Wang et. al., 2008). Genomic DNA was extracted from T cells transduced with SNIPR receptor circuits with a NucleoSpin Tissue kit (Macherey-Nagel) and digested with 40 IU of BamHI-HF and EcoRI-HF (New England Biolabs) at 37°C for 1 hour. ddPCRs amplifying HIV-1 Ψ and human TERT (hTERT) in duplex were set up and analyzed using PCR primers and protocols described previously (Wang et. al., 2008). The hTERT primers were 5'-GGCACACGTGGCTTTTCG-3' and 5'-GGTGAACCTCGTAAGTTTATGCAA-3'. The HIV-1 Ψ primers were 5'-TACTGACGCTCTCGCACC-3' and 5'-TCTCGACGCAGGACTCG-3'. The hTERT probe was 5'-TCAGGACGTCGAGTGGACACGGTG-3' with SUN dye and ZEN/IBFQ double quenchers. The HIV-1 Ψ probe was 5'-ATCTCTCTCTCTCTCTCGCCTC-3' with a 6-FAM dye and ZEN/IBFO double quenchers. PCRs were set up in accordance with ddPCR Supermix for Probes (No dUTP) guidelines (Bio-Rad) and droplets were generated using a QX200 Droplet Generator (Bio-Rad). The PCR program was one cycle at 95°C for 10 minutes, followed by 40 cycles at 94°C for 30 minutes and at 60°C for 1 minute, then one cycle at 98°C for 10 minutes. Samples were immediately analyzed by a QX100 Droplet reader using QuantaSoft software (Bio-Rad). Vector copy number was calculated using the formula: $2 \times (\text{copies of HIV-1 } \Psi) / (\text{copies of hTERT}).$

RNA-seq sample preparation— 4×10^6 primary human CD3+ T cells with and without SNIPR circuits were co-cultured 1:1 with K562^{CD19+} target cells for 48 hours. Following circuit induction, 2×10^6 T cells T cells were sorted, washed with PBS, flash frozen, and submitted to Genewiz for mRNA extraction (polyA selection), library preparation, and next-generation sequencing (Illumina, 2×150 bp, ~350M PE reads).

In vivo assays—For anti-ALPPL2 SNIPR→anti-HER2 CAR circuit testing, NOD.Cg-Prkdc^{scid}II2rg^{tm1WjI}/SzJ (NSG) mice between 8–12 weeks of age were injected subcutaneously with 4×10^{6} SK-OV- $3^{ALPPL2/HER2}$ target cells into the left flank and 4×10^{6} SK-OV- 3^{HER2} control cells into the right flank. 8 days post tumor injection, 1.5×10^{6} of untransduced bulk CD3+ T cells, anti-HER2 CAR-T cells, or anti-ALPPL2 SNIPR→anti-HER2 CAR circuit T cells were injected retro-orbitally, and tumor volume was measured by caliper regularly. For SK-OV-3 tumor T cell analysis, NSG mice were injected subcutaneously with 2.5×10^{6} SK-OV- $3^{ALPPL2/HER2}$ target cells into the left flank and 2.5×10^{6} SK-OV- 3^{HER2} control cells into the right flank. 33 days post tumor injection, 1.5×10^{6} of anti-ALPPL2 SNIPR-anti-HER2 CAR circuit T cells were injected retro-orbitally. 16 days post T cell injection, mice were sacrificed and T cell presence in the spleen, left, and right tumors was measured using flow cytometry.

For anti-ALPPL2 SNIPR→anti-Mesothelin CAR circuit testing, NSG mice between 8–12 weeks of age were injected subcutaneously with 4×10^6 M28^{ALPPL2/MESO} target cells into the left flank and 4×10^6 M28^{ALPPL2KO/MESO} control cells into the right flank. 10 days post tumor injection, 3×10^6 of untransduced bulk CD3+ T cells, anti-MESO CAR-T cells, or anti-ALPPL2 SNIPR-anti-MESO CAR single vector circuit T cells were injected retro-orbitally and tumor volume was measured by caliper every few days.

For anti-CD19 SNIPR—anti-BCMA CAR circuit testing, NSG mice between 8–12 weeks of age were implanted with either 1×10^{6} K562^{CD19+/BCMA+} tumor cells subcutaneously in the left flank alone or with an additional 1×10^{6} K562^{BCMA+} tumor cells subcutaneously in the right flank. Four days after tumor implantation, 2.5 or 3×10^{6} engineered primary human CD4+ and CD8+ T cells (total of 5 or 6×10^{6} T cells) were intravenously infused through tail vein injection. Tumor volume was monitored via caliper regularly.

QUANTIFICATION AND STATISTICAL ANALYSIS

RNA-seq analysis—RNA-seq analysis was performed by Genewiz as follows. Reads were trimmed (Trimmomatic v.0.36) and mapped to the 30-574668504_GRCh38 reference genome available on ENSEMBL plus SNIPR circuit sequences using STAR aligner v.2.5.2b. Unique gene hit counts were calculated by using featureCounts from the Subread package v.1.5.2, TPM plots were generated using R, and gene expression analysis was performed using DESeq2.

In vivo and *in vitro* statistical analysis—Statistics for tumor measurements were calculated using one-way analysis of variance (ANOVA) with Dunnet's test post hoc. Tumor takedown MFI statistics were calculated using Mann-Whitney U-test. *In vitro* reporter induction MFI statistics were calculated using unpaired T tests. P-values less than 0.05 were considered significant. Incucyte images were analyzed using the IncuCyte S3 Software (Essen Bioscience) to detect and count the number of mKate2+ nuclei per image.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

I.Z. is funded by an F30 fellowship from the National Cancer Institute (5F30CA250247-02). R.L. was supported by a T32 training grant (5T32AI07334-29). K.T.R. acknowledges funding from the Parker Institute for Cancer Immunotherapy and an NIH Director's New Innovator Award (DP2 CA239143). This work was also supported by NIH grant R01EB029483 (K.T.R., A.S.K.). A.S.K. acknowledges funding from a DARPA Young Faculty Award (D16AP00142), NIH Director's New Innovator Award (1DP2AI131083), and DoD Vannevar Bush Faculty Fellowship (N00014-20-1-2825). We acknowledge the PFCC supported in part by Grant NIH P30 DK063720 and by the NIH S10 Instrumentation Grant S10 1S10OD021822-01.

REFERENCES

- Barnea G, Strapps W, Herrada G, Berman Y, Ong J, Kloss B, Axel R, and Lee KJ (2008). The genetic design of signaling cascades to record receptor activation. Proc Natl Acad Sci U S A 105, 64–69. [PubMed: 18165312]
- Beel AJ, and Sanders CR (2008). Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci 65, 1311–1334. [PubMed: 18239854]
- Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA, and Israël A (2000). A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 5, 207–216. [PubMed: 10882063]
- Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, and Shepard HM (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proceedings of the National Academy of Sciences 89, 4285–4289.

- Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, et al. (2021). SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci. Transl. Med. 13, eabe7378. [PubMed: 33910979]
- Coleman HA, Labrador J-P, Chance RK, and Bashaw GJ (2010). The Adam family metalloprotease Kuzbanian regulates the cleavage of the roundabout receptor to control axon repulsion at the midline. Development 137, 2417–2426. [PubMed: 20570941]
- Daringer NM, Dudek RM, Schwarz KA, and Leonard JN (2014). Modular Extracellular Sensor Architecture for Engineering Mammalian Cell-based Devices. ACS Synth. Biol. 3, 892–902. [PubMed: 24611683]
- De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, et al. (1999). A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518–522. [PubMed: 10206645]
- Ellis GI, Sheppard NC, and Riley JL (2021). Genetic engineering of T cells for immunotherapy. Nature Reviews Genetics 1–21.
- Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJC, Hamieh M, Cunanan KM, Odak A, Gönen M, and Sadelain M (2017). Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117. [PubMed: 28225754]
- Fridy PC, Li Y, Keegan S, Thompson MK, Nudelman I, Scheid JF, Oeffinger M, Nussenzweig MC, Fenyö D, Chait BT, et al. (2014). A robust pipeline for rapid production of versatile nanobody repertoires. Nat Methods 11, 1253–1260. [PubMed: 25362362]
- Gordon WR, Roy M, Vardar-Ulu D, Garfinkel M, Mansour MR, Aster JC, and Blacklow SC (2009). Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood 113, 4381–4390. [PubMed: 19075186]
- Guedan S, Calderon H, Posey AD, and Maus MV (2019). Engineering and Design of Chimeric Antigen Receptors. Molecular Therapy - Methods & Clinical Development 12, 145–156. [PubMed: 30666307]
- Haapasalo A, and Kovacs DM (2011). The many substrates of presenilin/γ-secretase. J Alzheimers Dis 25, 3–28. [PubMed: 21335653]
- Hayward AN, Aird EJ, and Gordon WR (2019). A toolkit for studying cell surface shedding of diverse transmembrane receptors. ELife 8, e46983. [PubMed: 31172946]
- Hernandez-Lopez RA, Yu W, Cabral KA, Creasey OA, Lopez Pazmino M. del P., Tonai Y, De Guzman A, Mäkelä A, Saksela K, Gartner ZJ, et al. (2021). T cell circuits that sense antigen density with an ultrasensitive threshold. Science 371, 1166–1171. [PubMed: 33632893]
- Huppert SS, Le A, Schroeter EH, Mumm JS, Saxena MT, Milner LA, and Kopan R (2000). Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1. Nature 405, 966–970. [PubMed: 10879540]
- Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N, Montgomery G, Liu B, and Roybal KT (2021). SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci. Transl. Med. 13, eabd8836. [PubMed: 33910981]
- Israni DV, Li H-S, Gagnon KA, Sander JD, Roybal KT, Joung JK, Wong WW, and Khalil AS (2021). Clinically-driven design of synthetic gene regulatory programs in human cells (Synthetic Biology).
- Kandachar V, and Roegiers F (2012). Endocytosis and control of Notch signaling. Current Opinion in Cell Biology 24, 534–540. [PubMed: 22818956]
- Klebanoff CA, and Restifo NP (2016). Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells. Cell 167, 304–306. [PubMed: 27716501]
- Kopan R, and Ilagan MXG (2009). The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216–233. [PubMed: 19379690]
- Kroeze WK, Sassano MF, Huang X-P, Lansu K, McCorvy JD, Giguère PM, Sciaky N, and Roth BL (2015). PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat Struct Mol Biol 22, 362–369. [PubMed: 25895059]
- Lambrecht BN, Vanderkerken M, and Hammad H (2018). The emerging role of ADAM metalloproteinases in immunity. Nat Rev Immunol 18, 745–758. [PubMed: 30242265]
- Lasek W, Zago d on R, and Jakobisiak M (2014). Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 63, 419–435. [PubMed: 24514955]

Cell. Author manuscript; available in PMC 2023 April 14.

- Le Borgne R (2005). The roles of receptor and ligand endocytosis in regulating Notch signaling. Development 132, 1751–1762. [PubMed: 15790962]
- Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P, et al. (2012). Exploiting a natural conformational switch to engineer an interleukin-2 "superkine." Nature 484, 529–533. [PubMed: 22446627]
- Li N, Wang Y, Forbes K, Vignali KM, Heale BS, Saftig P, Hartmann D, Black RA, Rossi JJ, Blobel CP, et al. (2007). Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J 26, 494–504. [PubMed: 17245433]
- Majzner RG, and Mackall CL (2018). Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov 8, 1219–1226. [PubMed: 30135176]
- Moretti J, and Brou C (2013). Ubiquitinations in the Notch Signaling Pathway. IJMS 14, 6359–6381. [PubMed: 23519106]
- Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, and Rosenberg SA (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18, 843–851. [PubMed: 20179677]
- Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan C-T, Song H, et al. (2012). Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma. Human Gene Therapy 23, 1043–1053. [PubMed: 22780919]
- Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, and Lim WA (2016). Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell 164, 780–791. [PubMed: 26830878]
- Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ, Ray WJ, and Kopan R (2000). A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell 5, 197–206. [PubMed: 10882062]
- Okochi M (2002). Presenilins mediate a dual intramembranous gamma-secretase cleavage of Notch-1. The EMBO Journal 21, 5408–5416. [PubMed: 12374741]
- Pachella LA, Madsen LT, and Dains JE (2015). The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma. J Adv Pract Oncol 6, 212– 221. [PubMed: 26557408]
- Porter DL, Levine BL, Kalos M, Bagg A, and June CH (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365, 725–733. [PubMed: 21830940]
- Roscilli G, Rinaudo CD, Cimino M, Sporeno E, Lamartina S, Ciliberto G, and Toniatti C (2002). Long-term and tight control of gene expression in mouse skeletal muscle by a new hybrid human transcription factor. Mol Ther 6, 653–663. [PubMed: 12409264]
- Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, Walker WJ, McNally KA, and Lim WA (2016a). Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell 167, 419–432.e16. [PubMed: 27693353]
- Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, and Lim WA (2016b). Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. Cell 164, 770–779. [PubMed: 26830879]
- Seki M, Watanabe A, Enomoto S, Kawamura T, Ito H, Kodama T, Hamakubo T, and Aburatani H (2010). Human ROBO1 is cleaved by metalloproteinases and gamma-secretase and migrates to the nucleus in cancer cells. FEBS Lett 584, 2909–2915. [PubMed: 20471383]
- Srivastava S, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K, Smythe KS, Dudakov JA, Pierce RH, Rader C, et al. (2019). Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. Cancer Cell 35, 489–503.e8. [PubMed: 30889382]
- Toda S, Blauch LR, Tang SKY, Morsut L, and Lim WA (2018). Programming self-organizing multicellular structures with synthetic cell-cell signaling. Science eaat0271.
- Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, et al. (2015). Tissue-based map of the human proteome. Science 347, 1260419–1260419. [PubMed: 25613900]

- Vooijs M, Schroeter EH, Pan Y, Blandford M, and Kopan R (2004). Ectodomain shedding and intramembrane cleavage of mammalian Notch proteins is not regulated through oligomerization. J Biol Chem 279, 50864–50873. [PubMed: 15448134]
- Wang Y, Bergelson S, and Feschenko M (2018). Determination of Lentiviral Infectious Titer by a Novel Droplet Digital PCR Method. Human Gene Therapy Methods 29, 96–103. [PubMed: 29378428]
- Weber EW, Parker KR, Sotillo E, Lynn RC, Anbunathan H, Lattin J, Good Z, Belk JA, Daniel B, Klysz D, et al. (2021). Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786. [PubMed: 33795428]
- Williams JZ, Allen GM, Shah D, Sterin IS, Kim KH, Garcia VP, Shavey GE, Yu W, Puig-Saus C, Tsoi J, et al. (2020). Precise T cell recognition programs designed by transcriptionally linking multiple receptors. Science 370, 1099–1104. [PubMed: 33243890]
- Xu HE, Rould MA, Xu W, Epstein JA, Maas RL, and Pabo CO (1999). Crystal structure of the human Pax6 paired domain-DNA complex reveals specific roles for the linker region and carboxyterminal subdomain in DNA binding. Genes Dev 13, 1263–1275. [PubMed: 10346815]
- Yamamoto S, Charng W-L, and Bellen HJ (2010). Endocytosis and Intracellular Trafficking of Notch and Its Ligands. In Current Topics in Developmental Biology, (Elsevier), pp. 165–200.

HIGHLIGHTS

• SyNthetic Intermembrane Proteolysis Receptors exhibit modularity

- SNIPRs can be rationally optimized for sensitivity and strength of gene regulation
- SNIPRs are compatible with a range of human and programmable transcription factors
- Humanized SNIPR→CAR-T cells exhibit potent and precise anti-tumor activity *in vivo*




Figure 1. Design of synthetic RIP receptors for customized antigen-dependent gene regulation in therapeutic cells.

(A) Design of Synthetic Intramembrane Proteolysis Receptors. Receptors are comprised of a ligand binding domain (LBD), an extracellular domain (ECD), a transmembrane domain (TMD), a juxtamembrane domain (JMD), and a transcription factor (TF). Receptor circuits are designed to maximize clinical translation potential (**B**). A synRobo receptor replaces the Notch1 core with one from human Robo1. Compared to synNotch, a synRobo receptor fails to induce BFP. By replacing the TMD and JMD of Robo1 with those of Notch1, control of BFP production is lost. Deletion of a known ADAM10 cleavage site in the Robo1

ECD rescues ligand-dependent receptor behavior. (C) Same as B, but with minimal SNIPRs constructed using simple $(GGS)_n$ ECDs, and the TMD/JMD from Notch1. Statistics were calculated using unpaired T-tests, ***P 0.001.




Figure 2. The ECD module defines activation triggers and diversifies sensor functions.

(A) SNIPR ECDs with exposed cleavage sites display ligand-independent signaling. Deleting the NRR from synNotch produces a receptor that is sensitive to both ligand and TCR stimulation. A variety of hinge domains utilized in CARs also demonstrate ligand-dependent signaling. (B) Same as A, but with two methods of T cell stimulation. A SNIPR with the Notch1 NRR core domain displays enhanced activation with a Bi-specific T cell Engager (BiTE) targeting a K562 antigen, and a co-expressed second-generation CAR targeting a separate antigen. A SNIPR with a truncated Notch1 NRR activates with these stimuli independent of the presence of ligand. (C) Same as A, but with variations of the CD8α Hinge. The CD8α Hinge can be optimized to enhance SNIPR expression and activation. Statistics were calculated using unpaired T-tests, ***P 0.001.

Cell. Author manuscript; available in PMC 2023 April 14.

Zhu et al.

Page 25




Figure 3. Transmembrane and juxtamembrane domain libraries enable modular assembly of SNIPR architectures.

(A) To identify functional receptor TMDs and JMDs for modular assembly, 88 TMDs and 76 JMDs were cloned into a human synNotch scaffold, replacing either the Notch1 TMD or JMD, respectively. Jurkat T cells expressing an inducible BFP reporter were transduced with these SNIPR libraries in an arrayed format. (B) Normalized results of TMD screening in Jurkat T cells. An alignment of the best performing TMDs shows a common Gly-Val motif (Dark blue = >80% agreement with consensus sequence, blue = >60% agreement, light blue = >40% agreement). An alanine scan of the human Notch1 TMD in primary T cells supports the importance of this motif. (C) Same as B, but with the JMD library. High-performing JMDs are strongly basic at their N-termini and may include polar residues but not acidic or hydrophobic residues. (D) Compared to a reference SNIPR containing the Notch1 TMD/JMD, a SNIPR containing the CLSTN2 TMD/JMD is inactive, but receptor function is restored when the CLSTN2 JMD is replaced with the Notch1, AGER or PTPRF JMD.




Figure 4. Enhanced sensitivity and tunable gene regulation through SNIPR engineering. (A) From analyzing activity of high-performing SNIPR-BFP circuits, the Notch1 TMD was selected for further testing. Three JMDs and two TMD alanine mutants were selected to produce a wide output range. (B) K562 cells transduced with a doxycycline-inducible FLAG-tagged ALPPL2 cassette express ALPPL2 in a dose-dependent manner. (C) CD4+ T cells expressing anti-ALPPL2 SNIPR-MCAM CAR circuits were co-incubated with sender cells for 48 hours and CAR output was measured using a t2a GFP system. (D) Graphical representation of C. (E) Supernatant IL-2 concentration was assayed using ELISA. (F) T cells stained with Cell Trace Violet were co-incubated with irradiated sender cells in media without IL-2 for 9 days. T cell proliferation was measured using flow cytometry.

Zhu et al.






Figure 5. Humanization of SNIPRs to reduce immunogenicity potential for cell-based therapies. (A) Humanized TF and RE construction. (B) Activity of fully humanized SNIPRs. (C) SNIPR receptor scaffold compatibility with humanized TFs. (D) Assessing SNIPR immunogenicity. 9mer peptide sequences for SNIPRs with Gal4-VP64, Pax6, and HNF1A transcription factors were assessed for MHC I immunogenicity. Relative immunogenic potential across receptors was examined by comparing immunogenicity scores in regions derived from non-contiguous human protein sources (highlighted in red dashed boxes). Average scores: Pax6 0.039, HNF1A 0.156, BBz 0.102. (E) HNF1A SNIPR RNAsequencing analysis. HNF1A SNIPR T cells were induced with target cells for 48 hours and sorted to remove targets for RNA-sequencing analysis. Correlation of transcriptomes against non-SNIPR T cells in two donors show few differences apart from SNIPR circuit components. Pearson correlation coefficients (left panel) were calculated for native transcripts (gray). Differential gene analysis shows few upregulated or downregulated genes

compared to control cells following circuit induction (right panel).

Zhu et al.





(A) Incucyte live cell imaging showing killing kinetics and specificity of humanized anti-ALPPL2 SNIPR \rightarrow anti-HER2 CAR circuits against SK-OV-3 ovarian tumor cells. (B) Quantitation of incucyte assay killing in (A). (C) Humanized SNIPR \rightarrow CAR circuits clear dual positive ALPPL2+/HER2+ SK-OV-3 tumors *in vivo*. Statistics calculated using one-way analysis of variance (ANOVA) with Dunnet's test post hoc comparing anti-HER2 CAR-T cells to circuit T cells (top) and untransduced T cells to anti-HER2 CAR and Circuit

T cells (**bottom**). ***P 0.001. (**D**) *In vivo* assessment of fully human SNIPR circuit activation and trafficking. (**E**) Quantitation of T cells in the spleen and tumors. (**F**) Circuit activation of humanized SNIPR circuits in the spleen and tumors. (**G**) Quantitation of CAR surface expression in (**F**). Statistics were calculated using Mann-Whitney U-test (**E** and **G**), **P 0.01.




Figure 7. Design framework for next generation synthetic receptors for custom transcriptional regulation in therapeutic cells.

SNIPRs can be built through design of the receptor ECD, TMD, and JMD. The receptor ECD represents the first regulatory site and affects receptor activation parameters, expression, and stringency for ligand. Several known C-terminal motifs in the receptor TMD, commonly found in the Notch and Calsyntenin families, appear to be important for receptor signaling. Highly basic residues in the receptor JMD are required for signaling, and the choice of JMD can strongly affect receptor expression and output levels. By combining these elements, clinically relevant SNIPRs can be built that utilize fully human proteins and are compact, highly expressed, and regulatable. Our SNIPR design framework opens the possibility to build customized precision cellular therapeutics.

Key resources table

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Myc-Tag (9B11) Mouse mAb	Cell-Signaling Technology	Cat#2233
PE anti-DYKDDDDK Tag Antibody	Biolegend	Cat#637310
Chemicals, peptides, and recombinant proteins	-	•
In-Fusion Snap Assembly Master Mix with Competent Cells	Takara	Cat#638951
N-Acetyl-L-cysteine (NAC)	Sigma-Aldrich	Cat#A9165
Human AB Serum	Valley Biomedical Inc.	Cat#HP1022
Recombinant human IL-2 protein	NCI BRB Preclinical Repository	https://ncifrederick.cancer.gov/ research/brb/
Mirus Trans-IT Lenti Transfection Reagent	Mirus	Cat#MIR6606
ddPCR Supermix for Probes (No dUTP)	Bio-rad	Cat#1863024
Critical commercial assays		
RosetteSep Human CD4+ T Cell Enrichment Cocktail	STEMCELL Technologies	Cat#15062
RosetteSep Human CD8+ T Cell Enrichment Cocktail	STEMCELL Technologies	Cat#15063
IL-2 Human Instant ELISA Kit	Thermo Fisher	Cat#BMS221INST
Experimental models: Cell lines		
LentiX 293T	Clontech	Cat#11131D
K562 myelogenous leukemia cells	ATCC	Cat#CCL-243
E6-1 Jurkat T cells	ATCC	Cat#T1B-152
K562 CD19 (CD19 extracellular domain_myctag_hPDGFRtransmembrane)	Roybal et al., 2016	N/A
K562 GFP	Roybal et al., 2016	N/A
K562 ALPPL2	Hyrenius-Wittsten et al, 2021	N/A
K562 TRE ALPPL2	Hyrenius-Wittsten et al, 2021	N/A
MDA-MB-468	ATCC	Cat#HTB-132
U87 MG	ATCC	Cat#HTB-14
U87 ^{EGFRviii}	Choe et al., 2021	N/A
M28 ^{MESO}	Hyrenius-Wittsten et al, 2021	N/A
M28 ^{MESO/ALPPL2KO}	Hyrenius-Wittsten et al, 2021	N/A
SK-OV-3	UCSF Cell and Genome Engineering Core	Cat#CCLZR377
SK-OV-3 ^{ALPPL2}	Hyrenius-Wittsten et al, 2021	N/A
Experimental models: Organisms/strains		
NOD scid IL-2Ry-/- (NSG) (8-12 weeks)	Jackson Laboratories	Cat#005557
Oligonucleotides		•
hTERT Probe: 5 ['] -(SUN)-TCAGGACGTCGAGTGGACACGGTG- (ZEN/IBFQ)-3 [']	IDT	N/A
HIV-1 ¥ Probe 5'-(FAM)-ATCTCTCTCTCTAGCCTC-(ZEN/ IBFQ)-3'	IDT	N/A
hTERT Forward Primer: 5'-GGCACACGTGGCTTTTCG-3'	IDT	N/A

REAGENT or RESOURCE	SOURCE	IDENTIFIER
hTERT Reverse Primer: 5'- GGTGAACCTCGTAAGTTTATGCAA-3'	IDT	N/A
HIV-1 Ψ Forward Primer: 5'-TACTGACGCTCTCGCACC-3'	IDT	N/A
HIV-1 Ψ Reverse Primer: 5'-TCTCGACGCAGGACTCG-3'	IDT	N/A
Recombinant DNA		
pHR_SFFV	Addgene	ID#79121
pHR_PGK	Addgene	ID#79120
pHR_Gal4UAS_PGK_mCherry	Addgene	ID#79124
pHR_Gal4UAS_tBFP_PGK_mCherry	Addgene	ID#79130
Software and algorithms		
Prism Version 9	Graphpad	N/A
FlowJo V10.7.1	FlowJo LLC	N/A
Jalview	Jalview	N/A
Incucyte Software v2018B	Sartorius	N/A
QuantaSoft	Bio-Rad	N/A

Cell. Author manuscript; available in PMC 2023 April 14.